Rhumbline Advisers Lannett CO Inc Transaction History

Rhumbline Advisers

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$4.17 - $5.74 $532,521 - $733,015	-127,703 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$5.28 - $9.64 $10,961 - $20,012	2,076 Added 1.65%	127,703 $674,000
Q4 2020 Feb 10, 2021	BUY	$5.75 - $7.13 $95,754 - $118,735	16,653 Added 15.28%	125,627 $819,000
Q3 2020 Nov 12, 2020	SELL	$4.9 - $7.12 $40,572 - $58,953	-8,280 Reduced 7.06%	108,974 $666,000
Q2 2020 Aug 13, 2020	SELL	$6.43 - $9.86 $50,687 - $77,726	-7,883 Reduced 6.3%	117,254 $851,000
Q1 2020 May 06, 2020	BUY	$6.36 - $10.05 $66,703 - $105,404	10,488 Added 9.15%	125,137 $870,000
Q4 2019 Feb 05, 2020	BUY	$8.49 - $12.81 $44,054 - $66,471	5,189 Added 4.74%	114,649 $1.01 Million
Q3 2019 Oct 23, 2019	BUY	$5.58 - $14.47 $20,869 - $54,117	3,740 Added 3.54%	109,460 $1.23 Million
Q2 2019 Aug 14, 2019	SELL	$5.22 - $9.08 $88 - $154	-17 Reduced 0.02%	105,720 $641,000
Q1 2019 May 01, 2019	BUY	$5.35 - $9.82 $25,417 - $46,654	4,751 Added 4.7%	105,737 $832,000
Q4 2018 Jan 31, 2019	BUY	$3.43 - $6.19 $52,791 - $95,270	15,391 Added 17.98%	100,986 $501,000
Q3 2018 Nov 07, 2018	BUY	$4.75 - $14.5 $33,188 - $101,311	6,987 Added 8.89%	85,595 $407,000
Q2 2018 Aug 06, 2018	BUY	$13.3 - $17.45 $46,510 - $61,022	3,497 Added 4.66%	78,608 $1.07 Million
Q1 2018 May 02, 2018	BUY	$14.7 - $24.95 $55,595 - $94,360	3,782 Added 5.3%	75,111 $1.21 Million
Q4 2017 Feb 09, 2018	BUY	$19.9 - $29.25 $171,418 - $251,959	8,614 Added 13.74%	71,329 $1.66 Million
Q3 2017 Nov 06, 2017	BUY	$15.1 - $19.25 $946,996 - $1.21 Million	62,715	62,715 $1.16 Million

Ticker LCI
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,960,000
Market Cap $1.29M
Description
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nas...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.